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    Esophageal cancer is one of the most common malignancies with a growing occurrence. It presently ranks 
ninth among the most frequent cancers in the world and the sixth leading cause of death from cancer. For a 
variety of reasons, the mainstream of patients with esophageal cancer is actually not suitable for 
Esophagectomy. More than 50% have locally advanced unresectable or metastatic tumors at diagnosis. 
Other reasons which exclude Esophagectomy include old age, comorbidity or refusal by the patient. For 
more advanced stages of esophageal cancers, the basis of non-surgical treatment is chemotherapy (CT) or 
radiotherapy (RT), either alone or in combination as chemoradiotherapy (CRT). The purpose of this study is 
to summaries and judgmentally analyzes current non-surgical treatments. Although the best treatment for 
locally advanced esophageal cancer is still being debated, the use of neoadjuvant chemoradiotherapy has 
gained acceptance. 
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INTRODUCTION 
    Esophageal cancer (EC) has been informed as 
the eighth most common cancer and the sixth 
most lethal cancer worldwide [1]. In 2012, 
400,000 patients died from esophageal cancer 
globally [2]. In the United States, EC is in 
charge for more than 4% of annual cancer-
related deaths and an estimated 16,980 cases of 
esophageal cancer were diagnosed in 2014, with 
15,590 deaths per year expected from the disease 
[3]. Institute of Public Health Research of 
Tehran University (IPHR) and the International 
Agency for Research on Cancer (IARC) have 
publicized that North-eastern Iran is a very high 
occurrence region for esophageal cancer [4-7]. 
There are two histological types of esophageal 
cancer with different pathologic features: 
esophageal squamous cell carcinoma (ESCC) 
and esophageal adenocarcinoma (EAC). 
Squamous-cell carcinoma ascends from the 
epithelial cells that line the esophagus. 
Adenocarcinoma arises from glandular cells 
existing in the lower third of the esophagus, 
often where they have already converted to 
intestinal cell type (a condition known as 
Barrett's esophagus) [8]. Squamous-cell 
carcinoma is linked to lifestyle factors such as 
smoking and alcohol while the occurrence of AC 
has been expanding due to a dramatic rise in the 
percentage of overweight and obese people 
leading to increases in gastro esophageal reflux 
disease [9] and this histological type has greatly 
increased in the last decade in several European 
countries and in the United States [10]; Tobacco 
is a risk factor for both types [11].  
Selection of treatment scheme depends mainly 
on the patient’s performance status, stage or 
extent of the disease, histology, and position of 
the primary tumor. The main curative treatment 
modalities are surgery and concurrent 
radiotherapy and chemotherapy [12]. 
Managing of locally advanced esophageal 
tumors has moved from surgery alone to 
multimodality approaches [13]. Over the last 20 
 




years, there has been a development in using 
combined chemotherapy with radiation therapy. 
For most of the patients suffering advanced 
illness, curative treatment left overs to be a 
challenge. To improve the deprived outcomes of 
locally advanced esophageal cancer, many 
treatment modalities have been attempted such 
as addition of adjuvant radiotherapy and/or 
chemotherapy, neoadjuvant radiotherapy and/or 
chemotherapy, and definitive chemoradiotherapy 
(CRT) with various radiation doses and 
techniques. Consequently multimodal therapies, 
including chemotherapy and radiotherapy were 
presented. This review summaries and 
judgmentally analyzes current non-surgical 
treatments. 
 
Treatment of locally advanced esophageal 
cancer 
Radiation Alone 
    Currently, radiotherapy is one of the chief, 
effective and relatively inoffensive curative 
modalities for esophageal carcinoma. It could be 
used for early stage and advanced diseases, and 
as a locally palliative treatment for metastatic 
disease. Radiotherapy is one of the main 
palliative approaches in patients with dysphagia 
[14]. It has been used definitively, both 
preoperatively and postoperatively. Definitive 
radiation results in poor local control and poor 
survival. Numerous studies looking at external-
beam radiotherapy treatment alone found 
significantly low 5-year survival rates ranging 
from 0 % to 21 % [15-18]. Earlam and Cunha-
Melo reviewed 49 series with 8,489 patients 
treated with radiation alone and found the 
survival rates to be 18% at 1 year, 8% at 2 years, 
and 6% at 5 years [19]. Recent clinical trials 
have shown radiotherapy as a singular modality 
to be lower advantageous than chemoradiation. 
In conclusion, radiation alone should only be 
considered for palliative treatment and should 
not be considered for curative intent [20]. But, 
patients who are unfortunate surgical risks and 
are incapable to bear chemotherapy, occasionally 
will need to be managed with radiation therapy 
alone with a small but real chance of survival. 
 
 
Principles of Radiation Therapy Planning 
Although radiotherapy has a clear role in the 
management of esophageal carcinoma, the 
challenge is in delivering the radiation dose 
precisely to minimize normal tissue toxicity. 
Radiotherapy for carcinoma of the esophagus 
presents a particularly difficult treatment 
planning problem. The planning target volume 
(PTV) is central, close to the spinal cord, and is 
almost completely surrounded by lung, a 
radiosensitive organ with a relatively low 
radiation tolerance [21] and definitions of the 
primary site of esophageal cancer and metastatic 
lymph nodes are essential [22]. Patient 
positioning in the lying position is preferable in 
thoracic lesions and is likely to move the 
esophagus further from the spinal cord. If the 
tumor is in the distal third or the celiac nodes are 
histologically or clinically positive, the target 
volume is enlarged to include this nodal volume. 
Doses to the spinal cord, heart, lungs, liver, and 
kidneys must be kept within the tolerance limits 
to reduce morbidity [15]. Three-dimensional 
conformal radiotherapy (3DCRT) improves the 
dose distribution in lesions and thereby allows 
significant increase of target dose and decrease 
of organ at risk (OAR) doses. A wide range of 
doses has been used with radiotherapy alone and 
will be a function of the tumor location and the 
normal tissue tolerance. 
Chemotherapy 
     The disappointment of surgery to medications 
in localized esophageal cancer is as a 
consequence of the great number of lymph node 
involvement and distant metastases before 
symptoms happen. Preoperative (neoadjuvant or 
induction) chemotherapy has been used in an 
attempt to decline tumor activity, increase 
resectability and improve disease-free and 
overall survival. Chemotherapy drugs come into 
bloodstream and spread in the body, so it is 
valuable for extended cancers. Depending on the 
type and stage of esophageal cancer, 
Fluorouracil, also called 5FU, Capecitabine, also 
called Xeloda (X), Cisplatin, or sometimes 
carboplatin is used. Polee et al [23] have 
evaluated  a  biweekly  combination  of  cisplatin  
 
 




and paclitaxel in a phase II study, with hopeful 
results. Objective responses occurred in 59% of 
patients (total no. of 49), with median survival of 
20 months and 32 months in patients who had 
disease responsive to chemotherapy; the 3-year 
survival rate was 32%. 
The two almost the same trials were done; Allum 
WH [24] used 2 cycles of cisplatin and 5FU, and 
the Kelsen DP [25] used similar drugs but with 3 
cycles. Allum WH experimental stated a positive 
outcome from pre-chemotherapy, but Kelsen DP 
reported that preoperative chemotherapy with a 
mixture of Cisplatin and fluorouracil did not 
improve overall survival between patients. 
However, in spite of the differing outcomes in 
those two trials, the most current pre-
chemotherapy trials announce positive results 
[26, 27]. Data suggest that managing systemic 
chemotherapy prior to surgery for esophageal 
cancer increases survival compared to surgery 
alone [28, 29] and that the addition of 
simultaneous radiotherapy improves therapeutic 
yield, increases rates of pathologic complete 
response, decreases rates of local tumor 
recurrence and improves survival rate [30-32]. 
Definite Chemoradiotherapy 
     The combined use of radiation therapy and 
chemotherapy in cancer treatment is a rational 
and functional approach that has already 
established favorable for several malignancies. 
Local control of the primary tumor mass (which 
can often be achieved by high-dose radiation), 
combined with systemic chemotherapy to control 
metastatic disease, should provide effective 
means to contest such a highly complex disease 
[33]. Many chemotherapy drugs which enhance 
effects of radiation provide even more impetus to 
integrate both modalities. The Radiation Therapy 
Oncology Group (RTOG) 85-01 trial was a 
randomized controlled comparison of definitive 
radiotherapy alone (64 Gy), and definitive 
concurrent chemoradiation (50 Gy delivered 
concurrently with 5-fluorouracil [5-FU] and 
Cisplatin). A statistically significant benefit was 
noted for overall survival among patients 
receiving concurrent chemoradiation [34, 35]. 
This study, however, was done in the 1980s 
when staging did not require CT scanning, which 
might have led to difference between study 
groups. A follow-up trial (RTOG 94-05) 
compared chemoradiotherapy regimens with 
radiation doses of 64.8 Gy or 50.4 Gy. The 
addition of chemotherapy increased the median 
survival from 8.9 to 12.5 months. The 2-, 5- and 
8-year overall survival was 38%, 27% and 22%, 
respectively in the combined therapy group; 
while the 2-year overall survival was only 10% 
in the patients given radiotherapy alone, and 
none survived 5 years [35]. On the basis of these 
results, 50.4 Gy is the standard dose used in the 
USA [1, 36]. It has confirmed that 
chemoradiotherapy is superior to radiotherapy in 
localized carcinoma of the esophagus [37]. All 
of these studies report a greater average 
existence in the chemoradiation arm vs. radiation 
alone. Thus, definitive chemoradiation vs. 
radiation alone seems to offer better therapeutic 
result. Moreover, proofs have confirmed that 
long-term outcomes after definitive 
chemoradiotherapy for stage I-III esophageal 
cancer is comparable to that following 
Esophagectomy [38, 39]. 
Chan, et al [40] indicated that in 82 patients 
undergoing definitive CRT, 5-year overall and 
disease-free survival was 25% and 23% versus 
23% and 21% in 81 patients receiving surgery 
alone; no statistical difference was originate 
between the two groups. To put it briefly, 
definitive chemoradiotherapy is an upright 
substitute plan for patients with esophageal 
cancer who are not appropriate for surgical 
resection. 
Adjuvant Chemoradiotherapy 
    Adjuvant chemoradiotherapy is part of a 
multimodality treatment method so as to develop 
existence results after surgery in esophageal 
cancer. From the INT 0116 study [41], adjuvant 
chemoradiotherapy was established as the 
standard treatment in patients with node-positive 
AC of the gastroesophageal junction(GEJ ). This 
trial casually allocated 556 patients resected GEJ 
or stomach AC following surgery to either 
observation or adjuvant therapy with 4 monthly 
cycles of bolus 5-fluorouracil (5-FU) and 
leucovorin combined with radiation to 45 Gy in 
25 fractions. With a median follow-up period of 
5 years, the 3-year survival rate was 50% in the 
CRT group vs. 41% in the surgery alone group 
 




(P=0.005). A Chinese study of stage II and III 
SCC of the esophagus was piloted where patients 
were randomly divided into three groups; 
surgery alone, preoperative chemoradiation and 
postoperative chemoradiation and OS was 
significantly better in patients treated with 
postoperative and preoperative chemoradiation 
compared to surgery alone [42]. However, a 
randomized trial of Tachibana et al failed to 
show a continued existence advantage of 
adjuvant chemoradiotherapy compared to 
adjuvant chemotherapy [43]. Based on the 
beyond trials, the patients probably benefit from 
postoperative chemoradiation will have either 
positive lymph nodes or positive margins. 
Neoadjuvant Chemoradiation 
    Neoadjuvant methodologies purpose to 
enhance existence level by downstaging the 
tumor and annihilate micro metastatic disease at 
prompt stage. A neoadjuvant CRT method to the 
administration of esophageal cancer has several 
benefits over postoperative treatment. Patients 
will endure treatment better preoperatively, as 
they are not subject to the extended 
physiological recovery post-Esophagectomy. 
Several randomized trials determine the benefits 
of neoadjuvant chemoradiotherapy [31, 42, 44, 
45]. The earliest trials of preoperative 
chemoradiation were based on the success of 
treating anal carcinoma. Franklin et al [46] 
treated 30 patients with 30 Gy/3 weeks 
concurrent with 5-FU (days 1-4 and 29-32) and 
Mitomycin C (day 1) followed by surgery (day 
49-64). Postoperatively, 20 Gy was delivered to 
patients with residual disease. Follow-up 
revealed that four of the six histologically 
negative disease-free patients were alive for 95 
to 190 weeks. One of the patients who refused 
surgery after radiation and chemotherapy was 
alive at 4 years. In Walsh TN et al study [47], 
patients received either surgery alone or two 
courses of neoadjuvant chemotherapy 
(Cisplatin/5-FU) with concurrent RT 40 Gy, 2.67 
Gy per fraction. A statistically significant 
survival benefit was noted for the 
chemoradiation group with a median survival of 
16 months  vs. 11 months based on the  intent  to  
treat analysis and 32 months vs. 11 months based 
on an analysis of actual treatment received. 
Three-year survival was also statistically 
significant favoring the chemoradiation arm 
(32% vs 6%, p=0.01). In Dutch CROSS trial 
[48], 366 patients were randomized to 
neoadjuvant CRT with 5 weekly cycles of 
paclitaxel (50 mg/m2) and carboplatin (AUC 2) 
combined with concurrent radiotherapy (41.4 Gy 
in 23 fractions) or surgery alone. Both the 
median survival and overall survival was higher 
in the CRT group (49.4 versus 24.0 months, P= 
0.003). 
Meta-analyses also propose the valuable effects 
of neoadjuvant chemoradiotherapy. Urschel [49] 
and Fiorica [50] distinctly analyzed 6 identical 
randomized controlled trials comparing 
preoperative radiochemotherapy plus surgery 
with surgery alone for esophageal cancer. They 
found that a complete pathological response to 
chemoradiotherapy occurred in 21% of patients. 
Compared with surgery alone, neoadjuvant 
chemoradiotherapy significantly improved 3-
year survival and reduced locoregional cancer 
recurrence (p = 0.016). 
 
RESULTS 
     Numerous tactics have been attempted over 
the last couple of decades to treat patients with 
carcinoma of the esophagus in order to decrease 
the local tumor burden and treatment of 
micrometastatic disease. In table 1 several meta-
analyses have been showed to determine the 
survival benefit of these treatments for 
esophageal cancer. These contain several 
combinations of radiation therapy, surgery, and 
chemotherapy. Chemoradiation has shown 
expectant results and seems to be superior to 
radiation therapy as the sole modality. Radiation 
therapy offers important palliation in patients 
with inoperable disease and is particularly 
beneficial in such a setting. There is a 
requirement for registering patients in sufficient 
numbers in prospective clinical trials that will 
allow clinicians to be able to describe the ideal 
sequencing and actual necessity of each 




































y + Surgery 
3 x Cis/5FU - 46 10 n/s n/s Definitive 
Boonstra 
et al [52] 
Chemotherap
y + Surgery 
2 x 
Cis/etoposide 




y + Surgery 
2 x Cis/5FU - 802 17 n/s 23 Definitive 
Maipang 
et al [54] 
Chemotherap









- 64 Gy/6.4 wks 60 9.3 n/s 0 Palliative 




- 70 Gy/35 
fractions 






















Cisplatin/5-FU 45 Gy/5 wks 97 32 n/s 48.6 Definitive 
Abbreviations: 5FU=5 fluorouracil, Cis=Cisplatin, n/s=not significant, wks=weeks 
 
CONCLUSION 
    In conclusion, patients with esophageal cancer 
who do not experience Esophagectomy will 
generally benefit from CRT.  
The data that support the use of radiation alone 
for curative intent are limited and definitive 
chemoradiation is a respectable strategy for the 
treatment of locally advanced unresectable 
esophageal cancer, but local control leftovers a 
problem, and it is necessary to explore potential 
ways of improving local control.  
Neoadjuvant chemoradiation provides a 
significant benefit over surgery alone for 
esophageal cancer and it remains the standard 
non-surgical treatment for more advanced stages 
of esophageal cancers. 
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